Paresh Vyas

MRCP FRCP FRCPath FMedSci

Professor of Haematology

Consultant Physician

Normal and Leukaemic stem/progenitor cell biology

Our aim is to characterise the heterogeneous populations of leukaemia propagating cells in adult and childhood Acute Myeloid Leukaemia (AML) at functional, genetic, epigenetic and molecular levels, eventually at a single cell level, to improve our basic understanding of leukaemia initiation and propagation. The ultimate aim is to translate this knowledge to improve survival rates in patients.

Biography

Paresh Vyas is Professor of Haematology at the University of Oxford. He studied medicine at Cambridge then Oxford. After completing his medical and haematology training in London, he did his PhD with Professor Doug Higgs and Professor Sir David Weatherall at the MRC Molecular Haematology Unit, Oxford. A three-year post-doctoral fellowship with Professor Stuart Orkin at Harvard University followed. He is a research-active Consultant Haematologist with a clinical practice in myeloid disorders: myelodysplastic syndrome, MDS, acute myeloid leukaemia, AML, and myeloproliferative disorders, MPD, as well as allogeneic stem cell transplant. His research in the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, focuses on molecular and cellular biology of AML and MDS with specific interest in purification and therapeutic targeting of myeloid stem cells. He studies single cell biology in normal and leukaemic haemopoiesis. He is on the UK AML and MDS clinical trial groups.

Key publications

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Turkalj S. et al, (2026), Blood, 147, 613 - 632

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17

GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells.

Turkalj S. et al, (2023), Cell Stem Cell, 30, 722 - 740.e11

C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid Progenitor.

Di Genua C. et al, (2020), Cancer Cell, 37, 690 - 704.e8

Recent publications

Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO).

Papayannidis C. et al, (2026), Oncol Ther

Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.

Turkalj S. et al, (2026), Blood, 147, 613 - 632

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML.

Nier S. et al, (2025), Future Oncol, 21, 3713 - 3719

ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia.

Vyas P. et al, (2025), Future Oncol, 21, 3721 - 3729

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.

Daver N. et al, (2025), Blood, 146, 601 - 611

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Zeidner JF. et al, (2025), Blood, 146, 590 - 600

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2025)

Detecting and quantifying clonal selection in somatic stem cells.

Körber V. et al, (2025), Nat Genet, 57, 1718 - 1729

Clonal tracing with somatic epimutations reveals dynamics of blood ageing.

Scherer M. et al, (2025), Nature, 643, 478 - 487

Protocol for high-quality RNA sequencing, cell surface protein analysis, and genotyping in single cells using TARGET-seq.

Jakobsen NA. et al, (2025), STAR Protoc, 6

Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation.

Hosseini A. et al, (2025), Nature, 642, 508 - 518

Genome-Wide Association Studies of Down Syndrome Associated Congenital Heart Defects Suggests a Genetically Heterogeneous Risk for CHD in DS.

Feldman ER. et al, (2025), Genet Epidemiol, 49

Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia.

Mannis GN. et al, (2025), EJHaem, 6

Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1.

Agarwal P. et al, (2025), Nature, 642, 201 - 211

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Russell NH. et al, (2025), J Clin Oncol, 43, 694 - 704

Fetal Liver-Restricted Leukemic Proliferation Via GATA1s-CSF2RB-MPL Axis In Down Syndrome

Vyas P. et al, (2025)

Risk Stratification in Older Intensively Treated Patients With AML.

Versluis J. et al, (2024), J Clin Oncol, 42, 4084 - 4094

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Genome-wide association studies of Down syndrome associated congenital heart defects.

Feldman ER. et al, (2024)

Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.

Aksöz M. et al, (2024), Sci Immunol, 9

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17

Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

Cogswell TJ. et al, (2024), RSC Med Chem, 15, 3495 - 3506

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies

Turkalj S. et al, (2024), BLOOD, 144, 642 - 644

A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.

Turkalj S. et al, (2023), STAR Protoc, 4

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.

Freeman SD. et al, (2023), Blood, 142, 1697 - 1707

Changing treatment changing prognosis of mutations.

Vyas P., (2023), Blood, 142, 1583 - 1585

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Daver NG. et al, (2023), J Clin Oncol, 41, 4893 - 4904

Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines.

Josa-Culleré L. et al, (2023), Eur J Med Chem, 258

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.

Lachowiez CA. et al, (2023), Blood Cancer Discov, 4, 276 - 293

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

An Overview of Targeted Therapies in Acute Myeloid Leukemia.

Turkalj S. et al, (2023), Hemasphere, 7

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Sallman DA. et al, (2023), J Clin Oncol, 41, 2815 - 2826

GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells.

Turkalj S. et al, (2023), Cell Stem Cell, 30, 722 - 740.e11

Author Correction: Pan-cancer analysis of whole genomes.

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium ., (2023), Nature, 614

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.

de Botton S. et al, (2023), Blood, 141, 156 - 167

Dysregulation of chromatin via H3K27 methylation underpins differentiation arrest in Isocitrate dehydrogenase-mutant Acute Myeloid Leukaemia

Silveira DRA. et al, (2023)

Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging

Jakobsen NA. et al, (2023)

Sustained MYB Activity Is Necessary for Oncogenic Transcription in KMT2A-Rearranged Acute Lymphoblastic Leukemia through Enhancer-Promoter Interactions and Epigenetic Modifications at Enhancers

Lau J. et al, (2023), BLOOD, 142

More publications

Cookies on this website

Contact information

Research groups

Websites

Research Projects Available

Paresh Vyas

Biography

Key publications

Recent publications